BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 9213321)

  • 21. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
    D'Andrea GM; Seidman AD
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-27-S13-44. PubMed ID: 9335514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical evaluation of docetaxel (Taxotere).
    Lavelle F; Bissery MC; Combeau C; Riou JF; Vrignaud P; André S
    Semin Oncol; 1995 Apr; 22(2 Suppl 4):3-16. PubMed ID: 7740328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel: a review of its pharmacology and clinical activity.
    Trudeau ME
    Can J Oncol; 1996 Jun; 6(1):443-57. PubMed ID: 8853517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Taxoids: effective agents in anthracycline-resistant breast cancer.
    Ravdin PM
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination versus sequential single-agent therapy in metastatic breast cancer.
    Miles D; von Minckwitz G; Seidman AD
    Oncologist; 2002; 7 Suppl 6():13-9. PubMed ID: 12454315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
    Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platinum compounds in the treatment of advanced breast cancer.
    Martín M
    Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of docetaxel/doxorubicin combination in metastatic breast cancer.
    Diéras V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):31-3. PubMed ID: 9364539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.
    Lissoni P; Bucovec R; Malugani F; Ardizzoia A; Villa S; Gardani GS; Vaghi M; Tancini G
    Anticancer Res; 2002; 22(2B):1131-4. PubMed ID: 12168912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.
    Bissery MC; Vrignaud P; Lavelle F
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):3-16. PubMed ID: 8604451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent progress in the clinical development of docetaxel (Taxotere).
    Hortobagyi GN
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-agent docetaxel (Taxotere) in randomized phase III trials.
    Burris HA
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution in the treatment of advanced breast cancer.
    Crown J
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
    Rivera E; Valero V; Cristofanilli M; Frye DK; Booser DJ; Rosales MM; Hortobagyi GN
    Cancer; 2002 May; 94(9):2321-6. PubMed ID: 12015755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of patients resistant to paclitaxel therapy.
    Valero V
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():17-9. PubMed ID: 8862705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
    Nabholtz JM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):7-13. PubMed ID: 10426453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
    Ravdin PM
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
    Sparano JA
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel-based combination chemotherapy for breast cancer.
    Hortobagyi GN
    Oncology (Williston Park); 1997 Mar; 11(3 Suppl 2):29-37. PubMed ID: 9110340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.